title: Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study.
abstract: OBJECTIVE
  To evaluate the predictive factors of open-angle glaucoma (OAG) in patients affected by ocular hypertension enrolled in the European Glaucoma Prevention Study (EGPS).
  
  
  METHODS
  Randomized, double-masked, controlled clinical trial.
  
  
  METHODS
  One thousand seventy-seven patients, > or =30 years old, were enrolled at 18 European centers. The patients met inclusion criteria: intraocular pressure, 22 to 29 mmHg; 2 normal and reliable visual fields (VFs) (on the basis of mean deviation and corrected pattern standard deviation [PSD]); and a normal optic disc, as determined by an optic disc reading center.
  
  
  METHODS
  Treatment with dorzolamide or a placebo (the vehicle of dorzolamide) in one or both eyes.
  
  
  METHODS
  Efficacy end points were VF and/or optic disc changes. Baseline demographic and clinical data were collected before randomization, except for corneal thickness measurements, which were determined during follow-up. Proportional hazards models were used to identify factors that predicted which participants in the EGPS had developed OAG.
  
  
  RESULTS
  In multivariate analyses, factors that predicted the development of OAG included older age (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.04-1.69), larger vertical cup-to-disc (C/D) ratio (HR, 1.34; 95% CI, 1.14-1.58), larger vertical C/D ratio asymmetry (HR, 1.46; 95% CI, 1.11-1.93), higher PSD (HR, 1.66; 95% CI, 1.15-2.38), and lesser central corneal thickness (HR, 1.32; 95% CI, 1.05-1.67).
  
  
  CONCLUSIONS
  Baseline age, vertical C/D ratio, vertical C/D ratio asymmetry, and PSD were good predictors of the onset of OAG in the EGPS. Central corneal thickness was found to be a powerful predictor of the development of OAG. The EGPS results agree with the findings of the Ocular Hypertension Treatment Study and support the need for a thorough evaluation of patients with ocular hypertension.
authors.affiliation: Università di Milano Bicocca, Policlinico di Monza, Via Amati 111, 20052, Monza, Mi, Italy. stefano.miglior@unimib.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Miglior
authors.forename: Norbert
authors.initials: N
authors.lastname: Pfeiffer
authors.forename: Valter
authors.initials: V
authors.lastname: Torri
authors.forename: Thierry
authors.initials: T
authors.lastname: Zeyen
authors.forename: Jose
authors.initials: J
authors.lastname: Cunha-Vaz
authors.forename: Ingrid
authors.initials: I
authors.lastname: Adamsons
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D004311:Double-Blind Method; D005060:Europe; D005260:Female; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000150:complications* / Q000188:drug therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014792:Visual Acuity
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide